Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) was the target of a large drop in short interest in June. As of June 30th, there was short interest totalling 43,000 shares, a drop of 18.1% from the May 30th total of 52,500 shares. Based on an average daily volume of 43,700 shares, the short-interest ratio is currently 1.0 days. Approximately 0.2% of the shares of the stock are short sold.
Institutional investors and hedge funds have recently modified their holdings of the company. Two Sigma Advisers LP grew its stake in Aquinox Pharmaceuticals by 154.1% in the 4th quarter. Two Sigma Advisers LP now owns 34,300 shares of the company’s stock worth $74,000 after acquiring an additional 20,800 shares during the period. Highbridge Capital Management LLC grew its stake in Aquinox Pharmaceuticals by 57.4% in the 4th quarter. Highbridge Capital Management LLC now owns 755,774 shares of the company’s stock worth $1,633,000 after acquiring an additional 275,666 shares during the period. Acadian Asset Management LLC grew its stake in Aquinox Pharmaceuticals by 22.1% in the 1st quarter. Acadian Asset Management LLC now owns 603,490 shares of the company’s stock worth $1,627,000 after acquiring an additional 109,350 shares during the period. Dimensional Fund Advisors LP grew its stake in Aquinox Pharmaceuticals by 27.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 350,009 shares of the company’s stock worth $756,000 after acquiring an additional 74,725 shares during the period. Finally, Geode Capital Management LLC grew its stake in Aquinox Pharmaceuticals by 2.6% in the 4th quarter. Geode Capital Management LLC now owns 170,483 shares of the company’s stock worth $368,000 after acquiring an additional 4,280 shares during the period. 71.69% of the stock is owned by institutional investors and hedge funds.
Shares of AQXP opened at $2.40 on Friday. The stock’s 50 day simple moving average is $2.42. Aquinox Pharmaceuticals has a 1-year low of $2.00 and a 1-year high of $3.44.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.09) earnings per share for the quarter.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers.
See Also: Why Dividend Stocks May Be Right for You
Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.